Validating the OCS‐Plus against a clinical standard: A brief report

Abstract

AbstractThis research aimed to determine the sensitivity and clinical validity of the OCS‐Plus, a stroke‐specific tablet‐based cognitive screening tool, in comparison with the MoCA, a routinely used screening tool, after stroke. Eighty‐six patients were recruited from Oxfordshire stroke wards over a 22‐month period and completed both screens. Overall, we found that the OCS‐Plus has good convergent validity and excellent sensitivity when compared with the MoCA. The OCS‐Plus is therefore of potential benefit to those seeking a sensitive screening tool.